Press release BoxID: 721231 (aap Implantate AG)
  • aap Implantate AG
  • Lorenzweg 5
  • 12099 Berlin
  • Contact person
  • Fabian Franke
  • +49 (30) 75019-134

aap is granted European patent for LOQTEQ®, taking an important step toward global patent protection of the LOQTEQ® portfolio

(PresseBox) (Berlin, ) aap Implantate AG (XETRA: AAQ.DE), a developer, manufacturer and distributor of innovative trauma products, announced that the European Patent Office will shortly grant it a key patent for the core technology of its LOQTEQ® locking and compression plate system. The European patent will protect the LOQTEQ® hole in its current marketing form and, with it, the technology's final development stage. The final patent grant now depends solely on the fulfilment of formal conditions such as payment of a patent fee. In the next step the European patent will be nationalised in many key markets in Europe and published in different languages. The LOQTEQ® technology will then enjoy direct patent protection in these countries. As aap Implantate AG was granted the corresponding US patent in October last year and the company also holds many other international LOQTEQ® patents, the European patent represents an important step towards a global patent protection for the LOQTEQ® portfolio.

"With this key patent for our innovative LOQTEQ® product family in the important European market we have reached another significant milestone", said Bruke Seyoum Alemu, CEO of aap Implantate AG. "One of aap's priorities is to build up a strong IP-based trauma portfolio around LOQTEQ®. The grant of the patent enables us to further strengthen and extend our competitive position in the trauma sector."

The LOQTEQ® product family holds numerous international patents that protect certain aspects of the stable-angle compression technology. The claims that the patent protects have led to a unique design combined with a high level of biomechanical stability. Advantages in respect of explantability were generated at the same time by reducing the risk that cold-welding poses.

"The European patent is for us a further proof of the success of our philosophy of developing innovative technologies in close cooperation with our customers", Bruke Seyoum Alemu said. "Our focus is always on ensuring that the resulting products offer our customers not only clinical but also economic advantages and thereby generate a sustainable benefit."